SEC Company Response from Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251) (CTXR) — Aug 6, 2018
Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)
Date: Aug. 6, 2018 · CIK: 0001506251 · Accession: 0001213900-18-010293
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226395
Letter
CITIUS PHARMACEUTICALS, INC.
Commerce Drive, First Floor
Cranford, New Jersey 07016
August 6, 2018
Via EDGAR Delivery
Securities and Exchange Commission
F Street, NE
Washington, D.C. 20549
Re: Citius Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-226395
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Citius Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective date of the above-referenced registration statement (the “Registration Statement”) so as to become effective on Wednesday, August 8, 2018, at 5:00 p.m. Eastern Time, or as soon thereafter as practicable.
The Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the Registration Statement.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Alexander Donaldson at (919) 781-4000. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to Mr. Donaldson via email at adonaldson@wyrick.com.
Very truly yours,
CITIUS PHARMACEUTICALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
CITIUS
PHARMACEUTICALS, INC.
11
Commerce Drive, First Floor
Cranford,
New Jersey 07016
August
6, 2018
Via
EDGAR Delivery
Securities
and Exchange Commission
100
F Street, NE
Washington,
D.C. 20549
Re: Citius
Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-226395
Ladies
and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Citius Pharmaceuticals, Inc. (the “Registrant”)
hereby requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action
to accelerate the effective date of the above-referenced registration statement (the “Registration Statement”) so
as to become effective on Wednesday, August 8, 2018, at 5:00 p.m. Eastern Time, or as soon thereafter as practicable.
The
Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration
Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act and the
Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the
Registration Statement.
Once
the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP,
by calling Alexander Donaldson at (919) 781-4000. We also respectfully request that a copy of the written order from the Commission
verifying the effective date and time of the Registration Statement be sent to Mr. Donaldson via email at adonaldson@wyrick.com.
Very truly yours,
CITIUS PHARMACEUTICALS, INC.
By:
/s/
Myron Holubiak
Myron Holubiak
Chief Executive Officer